Cecile Becker, MD
Neurology · Springfield, ILNPI 1750493540
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 72.2% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2020 at $8,687 and has fallen 84.1% since, to $1,377 in 2025. Among neurology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 725 payments — averaging $35.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$19K
- Teva Pharmaceuticals USA, Inc.$1K
- AstraZeneca$725
- Biohaven Pharmaceuticals, Inc.$673
- Bristol Myers Squibb$642
- Lilly USA, LLC$486
- plus $4K from 32 others
Across 3 payments — averaging $27,102 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$81K
What the payments were for
- Speaking & faculty fees$13,25052%
- Travel & lodging$1,2345%
- Food & beverage$10,71742%
- Education$5202%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 288 | $18,578 |
| Teva Pharmaceuticals USA, Inc. | 80 | $1,076 |
| AstraZeneca | 14 | $725 |
| Biohaven Pharmaceuticals, Inc. | 70 | $673 |
| Bristol Myers Squibb | 77 | $642 |
| Lilly USA, LLC | 26 | $486 |
| UCB, Inc. | 33 | $468 |
| Mallinckrodt Hospital Products Inc. | 10 | $359 |
| Acadia Pharmaceuticals Inc | 19 | $306 |
| Genentech USA, Inc. | 17 | $304 |
| Lundbeck LLC | 16 | $300 |
| Biohaven Pharmaceutical Holding Company Ltd. | 22 | $240 |
| Amgen | 11 | $190 |
| Biogen | 3 | $143 |
| Argenx US, Inc. | 2 | $123 |
| Jazz Pharmaceuticals Inc. | 2 | $113 |
| Abbott | 1 | $112 |
| Johnson & Johnson | 1 | $93 |
| Neurocrine Biosciences, Inc. | 5 | $87 |
| Kyowa Kirin, Inc. | 1 | $84 |
| Axsome Therapeutics, Inc. | 1 | $72 |
| Novartis | 2 | $59 |
| Acorda Therapeutics, Inc | 2 | $57 |
| EMD Serono, Inc. | 4 | $51 |
| Scilex Pharmaceuticals Inc. | 1 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Pfizer | 2 | $38 |
| Kaleo, Inc. | 1 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| SK Life Science, Inc. | 1 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $26 |
| Eisai Inc. | 1 | $24 |
| TG Therapeutics, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,721 in reported general payments places this provider in the 90th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 14 | $734,737 |
| BetaseronInterferon Beta-1b | 14 | $131,407 |
| Teriflunomide | 13 | $76,479 |
| BotoxOnabotulinumtoxina | 46 | $70,983 |
| NuplazidPimavanserin Tartrate | 12 | $59,940 |
| BriviactBrivaracetam | 28 | $59,301 |
| Nurtec OdtRimegepant Sulfate | 30 | $51,530 |
| RytaryCarbidopa/Levodopa | 34 | $33,599 |
| Lacosamide | 136 | $31,151 |
| NourianzIstradefylline | 12 | $22,202 |
| Pregabalin | 159 | $21,548 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 22 | $18,753 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $18,480 |
| UbrelvyUbrogepant | 19 | $18,170 |
| Entacapone | 64 | $14,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $725 | $734,73714 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $18,578 | $102,16176 claims |
| Acadia Pharmaceuticals IncNuplazid | $306 | $59,94012 claims |
| UCB, Inc.Briviact | $468 | $59,30128 claims |
| PfizerNurtec Odt | $38 | $51,53030 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $19 | $36,78171 claims |
| Kyowa Kirin, Inc.Nourianz | $84 | $22,20212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 790 neurology providers in Illinois.
Other neurology in Springfield
- Rodger ElbleSpringfield$47K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.